This review assessed the effectiveness and safety of using ephedrine or ephedra for weight loss or improving athletic performance. The authors concluded that ephedra and ephedrine provide modest, short-term improvements in weight loss, but that they are associated with increased rates of side-effects. These conclusions reflected the limited evidence available and are likely to be reliable.
Data extraction
Two reviewers independently extracted the data, and any disagreements were resolved by consensus. Data on the study design and execution, participants, therapies, weight loss, follow-up times and adverse events were extracted. Effect sizes (standardised mean differences) were calculated from the mean and standard deviation for every comparison of interest with respect to weight loss. Odds ratios (ORs) were calculated for adverse events.
Methods of synthesis
How were the studies combined? Studies of weight loss were combined in random-effects meta-analyses. Trials assessing athletic performance were too heterogeneous to be pooled statistically, so these were combined in a narrative summary. Pooled ORs for some adverse events with sufficient data were estimated by meta-analysis. Publication bias was assessed by evaluating funnel plots, and by conducting an adjusted rank correlation test and a regression asymmetry test.
How were differences between studies investigated?
Subgroups were identified based on the comparison employed in the trials. A chi-squared test for heterogeneity was carried out. Sensitivity analyses were also conducted to investigate the effects of attrition and quality, and a metaregression was performed to compare the monthly weight loss effect sizes across comparisons.
Results of the review
Twenty trials were included in the assessment of weight loss and eight in the assessment of athletic performance. It was unclear how many trials were RCTs or CCTs, or how many participants were included. A total of 117 studies were included in the review of adverse events: 52 controlled trials and 65 case reports or case series.
Weight loss.
Trials of ephedrine or ephedra for weight loss involved up to 6 months of treatment.
Five trials, which received quality scores between 1 and 3, compared ephedrine with placebo. The pooled estimate of the rate of weight loss was an effect size of -0.50 (95% confidence interval, CI: -0.85, -0.15), which translated to a monthly weight loss of 1.3 pounds more for ephedrine than for placebo. An analysis including only high-quality trials found a pooled estimate significantly lower than the main analysis (effect size -0.20, P=0.049). No statistical heterogeneity was identified (P=0.185).
Twelve trials compared ephedrine plus caffeine with placebo, of which six had a quality score of 3 or more. The pooled estimate of the rate of weight loss was an effect size of -0.85 (95% CI: -1.1, -0.61), which translated to a loss of 2.2 pounds more in the treatment group than in the placebo group. The results of the sensitivity analyses were not significantly different from the main analysis. There was no evidence of publication bias. The P-value from the chisquared test for heterogeneity was 0.073, although the directions of the effect sizes of the individual trials were consistent.
Three trials compared ephedrine plus caffeine with ephedrine alone, and the quality scores were between 1 and 3. The pooled estimate of the rate of weight loss for the combined group was an effect size of -0.31 (95% CI: -0.60, -0.02), which equated to a weight loss of 0.8 pounds per month more for ephedrine plus caffeine compared with ephedrine alone. No statistical heterogeneity was identified (P=0.966).
Two trials compared ephedrine with another active weight loss therapy. There were no statistically significant differences between the groups in either trial.
One trial, which received a quality score of 4, compared ephedra with placebo. This trial found a weight loss rate of 1.8 pounds per month greater in the ephedra group than in the placebo group (95% CI: -2.7, -1.0).
Four trials compared ephedra plus caffeine-containing herbs with placebo; two of the trials received a quality score of 5 and two received a score of 2. The pooled estimate of the rate of weight loss was an effect size of -0.81 (95% CI: -1.12, -0.51), which translated to a weight loss of 2.1 pounds more in the treatment group than in the placebo group. There was no evidence of publication bias and no statistical heterogeneity was identified (P=0.689).
The meta-regression across all trials showed that all effect sizes for each comparison were significantly different from zero (i.e. all treatments were associated with significantly increased weight loss compared with placebo), with ephedrine plus caffeine and ephedra plus caffeine-containing herbs being somewhat more effective for weight loss than ephedrine alone.
Athletic performance.
Six small trials (with fewer than 24 participants) compared the effects of synthetic ephedrine with or without caffeine to caffeine and placebo on exercise parameters in healthy males. One of these trials assessed strength training and found a significant improvement in muscle endurance during the first of three repetitions. No other statistically significant differences were identified. One trial assessed the effects of ephedrine versus placebo or no treatment on 21 healthy young men. No statistical differences in athletic performance were identified.
Adverse events.
The pooled estimates showed that the treatment groups experienced significantly higher rates of psychiatric symptoms (8 trials; OR 3.64, 95% CI: 
Authors' conclusions
Ephedrine and ephedra promote modest short-term weight loss. However, there were no data regarding long-term weight loss. The use of ephedra or ephedrine and caffeine was associated with an increased risk of heart palpitations or psychiatric, autonomic, or upper gastrointestinal symptoms.
CRD commentary
The inclusion criteria were clear in terms of the interventions, outcomes and study designs eligible for inclusion in the review. The search was extensive with attempts to minimise language and publication bias. The authors used appropriate measures to minimise bias and error in the study selection and data extraction processes of the review. The quality of the included studies was assessed using a validated measure (although not the most informative) and the findings were incorporated into sensitivity analyses of the results. Meta-analytic methods were employed where appropriate, and the methods of analyses and the assumptions employed were explicit. The authors' cautious conclusions accurately reflect the limitations of the evidence available to the review, and are likely to be reliable.
Implications of the review for practice and research
Practice: The authors did not state any implications for practice.
Research: The authors stated that long-term assessments of the efficacy of ephedra or ephedrine for promoting weight loss are required. Studies evaluating the effect of repeated use of ephedra or ephedrine on athletic performance in women and adolescents, and in individuals who represent the general population, are needed. There is also a need for a study assessing the possible association of ephedra or ephedrine and the occurrence of serious adverse events.
